Background. Artemisinin-based drug combinations are the mainstay in the fight against drug-resistant malaria in Africa. Currently available antimalarial drug combinations that include artemisinins are pharmacokinetically unmatched and are therefore potentially increasing the risk of selection of resistant mutants in areas in which the rate of transmission of malaria is high. We tested the potential value of artemisinin-based combination therapy with a short elimination half-life for the treatment of uncomplicated Plasmodium falciparum malaria in subSaharan Africa.
Various drugs have been studied in combination with artemisinin derivatives [5] . To date, the underlying principle has been to combine artemisinins with drugs that have a long plasma elimination half-life. Although good results have been obtained in regions of low endemicity for malaria, combination therapy involving drugs with different pharmacokinetic profiles seems to be inappropriate for patients in areas in which the rate of transmission of malaria is high, because of the increased risk of selection of drug-resistant mutants that results from prolonged exposure to subtherapeutic drug levels of the slowly eliminated drug in the combination [6, 7] . Combination therapy that involves the use of drugs that have a fast elimination time is thought to lead to reduced selection of and mutual protection against resistant isolates [4, 7] . However, to date, no clinical trial of matching artemisinin-based combina-tion regimens with short half-lives has been reported from subSaharan Africa [5] .
Clindamycin was chosen as the most promising drug with a short half-life that could be used in combination with artemisinin derivatives, on the basis of encouraging results from animal models, in vitro studies of Plasmodium falciparum, and one report of the use of sequential treatment with artesunate and clindamycin for Brazilian children [8] [9] [10] . Characterized by slow but thorough antimalarial activity, clindamycin exhibits a remarkably short plasma half-life (2-4 h) and a good safety and tolerability profile in antimalarial therapy [11] . We compared the efficacy and tolerability of artesunate combined with clindamycin with the efficacy and tolerability of standard quinine-clindamycin therapy for the treatment of uncomplicated P. falciparum malaria in Gabonese children.
METHODS

Study area.
A clinical trial was conducted at the Medical Research Unit of the Albert Schweitzer Hospital in Lambaréné, Gabon, from December 2003 through May 2004. Lambaréné is a semiurban city of ∼30,000 inhabitants that is located amid the tropical rainforest of Gabon. Malaria transmission is perennial, and it has a hyperendemic pattern and an entomological inoculation rate of ∼50 infective bites per person per year [12] .
Study design and enrollment. The study was designed as an open-label, randomized, controlled clinical trial. One hundred children were enrolled in the study. Ethical clearance was obtained from the ethics committee of the International Foundation for the Albert Schweitzer Hospital in Lambaréné. Patients who presented at the outpatient department of the Albert Schweitzer Hospital were invited to participate in the study if they met the following criteria for inclusion: (1) age of 3-12 years, (2) the presence of microscopically confirmed P. falciparum monoinfection with signs and symptoms of uncomplicated malaria, (3) asexual parasitemia (1000-100,000 parasites/ mL of peripheral blood), (4) body weight of 10-70 kg, (5) ability to tolerate oral therapy, and (6) written, informed consent of the parents or legal representatives and oral consent of the child. Exclusion criteria consisted of the following: (1) signs and symptoms of severe malaria (as defined by WHO criteria [13] ), (2) current antibiotic treatment or a history of antimalarial drug use in the 7 days preceding presentation, (3) a hematocrit of !23%, (4) a WBC count of 1 cells/L, and (5) the 9 15 ϫ 10 presence of any other severe underlying disease.
Study flow. A study physician examined all patients at enrollment to assess vital signs, blood pressure, heart rate, and tympanic temperature. Capillary blood was drawn by fingerprick, to perform a complete blood count (QBC; Becton Dickinson) and thick blood smear. Thick smears were prepared and read according to the Lambaréné method [14] .
Randomization codes were computer generated in blocks of 10, placed in sealed envelopes, and provided to the Medical Research Unit at initiation of the study. The study physician opened each envelope containing the respective treatment allocation, only after each patient was judged to be eligible for inclusion in the study.
Study drugs were administered orally with water or other liquids, under the supervision of a study physician. For the first drug combination, artesunate, 2 mg/kg, was administered in combination with clindamycin, 7 mg/kg; for the second drug combination, quinine sulfate, 15 mg/kg, was administered in combination with clindamycin, 7 mg/kg. Drugs were administered every 12 h for a total of 6 doses. If vomiting occurred within 30 min after drug intake, the same dose was readministered. If vomiting occurred within 30 min after readministration of the dose, patients were withdrawn from the clinical trial and a "rescue treatment" was given. Artesunate (Arsumax; Sanofi-Synthélabo) was formulated as 50-mg tablets; quinine sulphate (Pharmamed), as 300-mg tablets; and clindamycin (Dalacin; Pfizer), as 75-mg and 150-mg capsules.
Patients were followed up twice daily for 3 days or until clinical signs resolved and negative results were obtained for 2 consecutive thick blood smears. Patients were encouraged to present to the Medical Research Unit if signs or symptoms reappeared. Follow-up visits were scheduled on days 7, 14, and 28 of follow-up. At each follow-up visit, vital signs and tympanic temperature were assessed, and a thick blood smear was examined. Complete blood counts were determined again on days 2 and 28 of follow-up. Dried capillary blood spots were obtained at enrollment and, again, if asexual parasitemia reappeared, to distinguish reinfections from recrudescent infections by use of PCR-based genotyping.
Laboratory analysis. DNA extraction and amplification of merozoite surface antigen 2 were performed as described elsewhere [15] . Parasite isolates recovered at enrollment and at the time of reappearance of asexual parasitemia were compared on the basis of their size and the number of fragments, and they were classified as recrudescing parasite strains or reinfections. There was no adjustment for a potentially confounding concurrent presence of sexual parasite stages at the time of reappearance of asexual parasites.
Sample-size calculation and outcome measurements. The primary objective of the clinical trial here was to obtain an estimate of the cure rate at follow-up day 28 that was associated with the use of a short-course regimen of artesunateclindamycin, to determine the prospects for the further development of artemisinin combinations that have a short elimination half-life. For sample-size calculation, the working hypothesis that was formulated was that artesunate-clindamycin therapy would be at least as efficacious as quinine-clin- Figure 1 . Flowchart of the enrollment and follow-up of patients participating in the present study damycin therapy. A sample size of 50 patients per treatment group was computed on the basis of the following assumptions: 98% efficacy of the standard medication, a cure rate associated with experimental therapy that was within the 7% of the cure rate associated with standard therapy, and a loss of 10% of patients to follow-up ( ; power, 80%) [16, 17] . The a p 0.05 primary end point of the study was the PCR-corrected cure rate for the per-protocol (PP) population. The secondary end point was the rate of adverse events in the 2 treatment groups.
The "cure rate" was defined as the proportion of patients who presented without reappearance of asexual parasitemia during the 28-day follow-up after initial clearance of parasites, as corrected by PCR genotyping. On the basis of current WHO guidelines, response to treatment was classified as "adequate," "early treatment failure" (occurring from days 1 to 3 of followup), or "late treatment failure" (occurring from days 4 to 28 of follow-up) [18] .
The intention-to-treat (ITT) population included all patients who received at least 1 dose of the study drugs. The PP population excluded patients who were noncompliant with the treatment regimen, had violated inclusion/exclusion criteria, were lost to follow-up, or were withdrawn from the study for reasons other than treatment-related adverse events or treatment failure. These patients were considered to have treatment failure in the ITT population (extreme-case scenario). Times to parasite clearance and fever clearance were secondary efficacy end points. Time to fever clearance was defined as the first of 2 subsequent measurements of a tympanic temperature of !37.5ЊC.
The end point for the safety and tolerability analysis was the proportion of subjects who experienced adverse events during the 28-day follow-up after initiation of treatment. Adverse events were segregated into serious and nonserious adverse events and were classified according to their severity (mild, moderate, or severe) and the causality of the study drugs (as judged by the study physician). Evaluation of measurements of safety and tolerability was performed for the ITT population.
Statistical evaluation and data management. Data were entered into patient record forms and were subsequently transferred into an electronic database (Filemaker Pro 5.5; Filemaker). Data in patient record forms were validated manually to produce a final database for further analysis. Statistical analysis was performed using a commercial software package (JMP, version 5.0; SAS Institute). Fisher's exact test was used for comparison of cure rates, and Student's t test was used for comparison of times to parasite clearance and fever clearance. Ninety-five percent confidence intervals and P values for testing of noninferiority of efficacy were calculated according to the method of Blackwelder [16] . For all tests performed, a p , and was the threshold for statistical significance. 0.05 P р .05
RESULTS
Study flow. Figure 1 shows a flowchart of patient enrollment and follow-up. The 100 patients who were included in the clinical trial were randomly assigned to the 2 treatment groups. Three patients received self-treatment with antimalarials during the course of the study. One patient missed 1 treatment visit, and another patient vomited readministered study drugs. One child was withdrawn from the study because he developed tinnitus during the treatment period. All these patients were excluded from the PP analysis and were classified as having treatment failure in the ITT analysis. One patient erroneously received a wrong a dose of quinine-clindamycin (quinine, 18.8 mg/kg, and clindamycin, 12.5 mg/kg). This patient developed malaria on day 14 of follow-up and was classified as having treatment failure in both the PP and the ITT analyses. For all other patients, follow-up was successful until day 28 of followup or until asexual parasitemia reappeared. At enrollment, patient characteristics and laboratory values were comparable in the 2 treatment groups (table 1) . Cure rates. Asexual parasitemia was readily cleared in all patients within the first week of treatment. Parasites were eliminated faster in the artesunate-clindamycin group than in the quinine-clindamycin group (mean time to parasite clearance, 29.3 h vs. 46.0 h), and patients in the artesunate-clindamycin group also experienced a faster recovery from fever (21.2 h vs.
h) (table 2).
Of the patients who were allocated to receive treatment with artesunate-clindamycin, 7 presented with reappearing parasitemia on day 21 of follow-up, and 3 presented with reappearing parasitemia on day 28 of follow-up. Four of the cases of reappearing parasitemia were found to be reinfections, according to the results of merozoite surface antigen-2 genotyping. Thus, the PCR-corrected cure rate associated with artesunate-clindamycin therapy was 87% (40 of 46 patients; 95% CI, 74%-94%) (table 2), and the respective uncorrected cure rate was 78% (36 of 46 patients; 95% CI, 64%-88%).
Two patients who received quinine-clindamycin presented with asexual parasitemia on day 14 of follow-up. A total of 8 patients who received quinine-clindamycin presented with asexual parasitemia during the 28-day follow-up. Five cases of reappearing parasitemia were found to be newly acquired infections, according to merozoite surface antigen-2 genotyping. The PCRcorrected cure rate in the PP population was, therefore, 94% for patients given quinine-clindamycin (45 of 48 patients; 95% CI, 83%-98%) (table 2), and the respective uncorrected cure rate was 83% (40 of 48 patients; 95% CI, 70%-91%).
No significant difference in the cure rate on day 28 was observed between treatment groups in the respective analyses. Statistical analysis testing for the noninferiority of efficacy of artesunate-clindamycin, compared with the standard quinineclindamycin regimen, showed that and for the P p .34 P p .49 ITT and PP populations, respectively. The evolution of hematological values was comparable in the 2 treatment groups, although the overall increase in the hematocrit during the 28-day follow-up was higher for the quinine-clindamycin group (table 3) . The gametocyte carrier rate at follow-up was similarly low in both groups (2 individuals in the artesunate-clindamycin group and 5 individuals in the quinine-clindamycin group) (table 3) .
Adverse events. Both treatment regimens were well tolerated, and no serious adverse event occurred in the trial. Six episodes of moderately severe adverse events were recorded. Adverse events judged to be at least probably associated with the study drugs occurred in 1 patient in the artesunate-clindamycin group (diarrhea) and in 2 children in the quinineclindamycin group (diarrhea and tinnitus). The patient who experienced tinnitus on the first day of follow-up had been assigned to the quinine-clindamycin group. He was withdrawn from the study and received successful treatment with sulfadoxine-pyrimethamine.
All remaining episodes of untoward experiences were mild in severity (table 4) . Gastrointestinal symptoms were the most common adverse events in the artesunate-clindamycin and quinine-clindamycin groups, and they included abdominal pain (11 vs. 12 patients), loose stool (9 vs. 12 patients), and increased stool frequency (defined by not more than 3 episodes of loose stool per day; 20 vs. 18 patients). For patients in the artesunateclindamycin and quinine-clindamycin groups, adverse effects other than common cold-like symptoms (13 vs. 8 patients), vomiting (5 vs. 6 patients), headache (4 vs. 2 patients), and skin efflorescence (4 vs. 2 patients) were rare. Adverse events associated with cinchonism (headache, tinnitus, and dizziness) were uncommon in patients in the artesunate-clindamycin and quinine-clindamycin groups (6 vs. 4 patients). No difference was found in the overall incidence of adverse events in the 2 treatment groups.
DISCUSSION
In the present study, a satisfactory efficacy of artesunate-clindamycin combination therapy was noted. The overall cure rate in the PP population was within the range of the cure rate associated with the standard quinine-clindamycin regimen. Although the P value associated with noninferiority testing was not statistically significant, this finding might be ascribed to the lower-than-predicted efficacy of the quinine-clindamycin regimen and the relatively small sample size of the study. Given the objective of estimating the overall prospect of further investigation of artemisinin-based combination regimens with short plasma half-lives, the cure rates that were observed look promising.
Times to fever clearance and parasite clearance, which are considered to be supportive evidence of antimalarial activity, were shorter in the artesunate-clindamycin group. This finding is in concordance with those of previous studies that established sesquiterpene lactones as the fastest-acting antimalarials known to date [4] . However, it is not yet clearly understood whether the faster reduction in the parasite load translates similarly to an improved clinical recovery and a lower mortality rate [5] .
The frequency of adverse events was comparable in the 2 groups. Of interest, the number of adverse events similar to those associated with cinchonism was not increased in the quinine-clindamycin group. Gastrointestinal adverse events were the most common side effects and were possibly attributable to the clindamycin component of the regimens. All of the reported gastrointestinal disturbances were of mild-to-moderate severity and ceased without medical intervention within a few days. Similarly, in a considerable number of clinical trials, clindamycin has been shown to be well tolerated when used as an antimalarial [11] . This finding is attributed to the relatively low dosage and short treatment duration used with clindamycin. Most antimalarial combinations tested to date and used in sub-Saharan Africa contain a slowly eliminated drug [5] ; such regimens include artesunate-amodiaquine [19] , artemether-lumefantrine [20] , and other artemisinin-based combinations. There are reports of only 3 drug combinations that deviate from this principle. Chlorproguanil-dapsone is an antimalarial combination treatment that has been registered for the treatment of uncomplicated malaria in sub-Saharan Africa [21] . It is characterized by a relatively short plasma half-life (20 h for chlorproguanil and 30 h for dapsone) and reasonable efficacy (96%) on day 14 of follow-up; however, cure rates at day 28 of follow-up are likely to be considerably lower. In this context, the 100% cure rate noted for artesunate-clindamycin on day 14 of follow-up in this trial is promising. Furthermore, the tolerability of artesunate and clindamycin seems to be favorable, and there seem to be no concerns about safety with regard to severe hematological side effects associated with chlorproguanil-dapsone [5, 21] .
Fosmidomycin-clindamycin is another antimalarial drug combination that has a short half-life, shows good efficacy, and results in equally fast parasite clearance and fever clearance because of the rapid action of fosmidomycin [22] . One possible advantage of artesunate-clindamycin, compared with fosmidomycin-clindamycin, might, however, be associated with the low gametocyte carrier rates noted in the course of convalescence after treatment initiation; these low rates may possibly lead to diminished recombination and transmission of drug- resistance genes during the sexual development of the parasite.
Further clinical exploration of this regimen is needed in subSaharan Africa. The third antimalarial combination therapy that consists of drugs with short half-lives is quinine-clindamycin, which was shown to be very efficacious and safe but, mainly because of quinine, not very well tolerated in African children with falciparum malaria [17, 23] . The direct comparison of the 2 regimens that contain clindamycin did not show any clinically relevant difference in safety and efficacy parameters in the present study.
A possible drawback of treatment involving drugs with short half-lives is the necessity of repeated dosing. Artesunate-clindamycin was administered every 12 h for 3 days. This regimen might be inconvenient enough to significantly hamper its effectiveness in routine use. Whether persistence of clinical symptoms during the 3 days of follow-up will help to maintain compliance should be addressed in future studies of effectiveness.
The use of clindamycin is not restricted in children or pregnant women, and similar evidence emerges for the use of artemisinins [5, 24, 25] . This is an invaluable advantage of this antimalarial combination, because children and pregnant women have the highest risk for malaria-associated morbidity and mortality in sub-Saharan Africa.
On the basis of the results of the present study, the development of artemisinin-based antimalarial combinations with short half-lives seems feasible. Artesunate-clindamycin, one of the candidate regimens for the therapy of uncomplicated malaria in areas of sub-Saharan Africa where there is a high rate of transmission of malaria, merits further clinical investigation.
